Latest Astrazeneca Plc (AZN) Headlines Morning
Post# of 85
Posted On: 03/14/2014 11:35:12 AM
Latest Astrazeneca Plc (AZN) Headlines
Morning Movers in Biotech: AstraZeneca PLC, Durata Therapeutics, Inc. and Intercept Pharmaceuticals,
George Budwell, The Motley Fool - Motley Fool - 2 hrs 30 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Fri Mar 14, 7:02AM CDT
AstraZeneca (NYSE:AZN) was downgraded from Neutral to Underweight at JP Morgan today. The stock closed yesterday at $65.27 on volume of 2.8 million shares, above average daily volume of 2.4 million. AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
AstraZeneca to Sell Cheshire Research Site - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:30AM CDT
AstraZeneca agreed to sell its Alderley Park center to Manchester Science Parks.
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
How Will This Latest Setback Affect Eli Lilly?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 11, 8:30AM CDT
Still struggling to revive its drought of approvals, especially after staunchly refusing to succumb to the rest of Big Pharma's strategy of mergers and acquisitions, Eli Lilly suffered another setback for its diabetes pipeline this week when the...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Key Pharmaceutical Executive Joins Mesoblast
GlobeNewswire - Mon Mar 10, 6:49PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former Chief Financial Officer of Novartis AG, has joined the Company to support the implementation of corporate finance and strategic objectives.
Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
M2 - Mon Mar 10, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k2mrld/investigation) has announced the addition of the "Investigation Report on China Budesonide Market, 2009-2018" report to their offering. Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year. Budesonide inhalation suspension (trade name ""Pulmicort Respules"") developed by Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It obtained import approval in China in November 2001. Statistics shows that there are more than 30 million asthma patients and over 0.3 billion people suffering from allergic rhinitis in China. According to CRI's investigation on certain sample hospital market in China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011, market growth has slowed down, but it still maintains an annual growth rate of 18%. In April 2013, the patent protection of asthma drug ""Pulmicort Respules"" produced by Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that this has paved the way for generic drug to occupy the market. Budesonide products in Chinese market are still mainly imported drugs from Astra Zeneca, but there are already some Chinese enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group) Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and finished drugs. Through this report, the readers can acquire the following information: - Incidence of Respiratory Disease in China - Market Share of Major Budesonide Manufacturers in Sample Hospitals in China - Sales price of Budesonide in Hospital Market in China - Production Status of Budesonide Generic Drug in China - Major Budesonide Manufacturers in China - Share of Budesonide in Different Dosage Forms in China Hospital Market - Prospect of China Budesonide Market The author recommends the report to the following: - Budesonide Manufacturers - Medical Institutions - Investors /Research Agencies Focusing on Respiratory Drug Market Key Topics Covered: 1 Relevant Concepts of Budesonide 2 Market Overview of Budesonide in China 3 Investigation on Sales Value of Budesonide in China, 2009-2013 4 Investigation on Market Share of Major Budesonide Manufacturers in China, 2009-2013 5 Investigation on Market Size of Budesonide by Dosage Form in China, 2009-2013 6 Reference Price of Budesonide Produced by Different Enterprises in China Hospital Market, 2013 7 Analysis on Major Budesonide Manufacturers in China, 2009-2013 8 Prospect of China Budesonide Market, 2014-2018 Companies Mentioned - AstraZeneca Australia - AstraZeneca plc. - Lunan Better Pharmaceutical Co., Ltd. - Synmosa Biopharma Corp. For more information visit http://www.researchandmarkets.com/research/k2...estigation
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Pulmonary Drug Delivery Systems Market Forecast, 2013 - 2019 Report
M2 - Fri Mar 07, 3:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/cm5685/pulmonary_drug) has announced the addition of the "Pulmonary Drug Delivery Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' This report studies the current scenario as well as the future market potential for pulmonary drug delivery systems, globally. The market for pulmonary drug delivery systems has been segmented into three major product types, namely, metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. The market for these systems has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence and technological developments. On the basis of therapeutic application, the market has been segmented into asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. Geographically, the market for pulmonary drug delivery systems has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. The report also provides a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global pulmonary drug delivery systems market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the global pulmonary drug delivery systems market such as AstraZeneca plc, CareFusion Corporation, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., 3M Health Care, Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Philips Respironics, Inc., Allied Healthcare Products, Inc., and GF Health Products Inc. Key Topics Covered: Preface Executive Summary Market Overview Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2011 - 2019 (USD Million) Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2011 - 2019 (USD Million) Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - 3M Health Care - Allied Healthcare Products, Inc. - AstraZeneca plc - Boehringer Ingelheim - CareFusion Corporation - GF Health Products, Inc. - GlaxoSmithKline plc - Merck & Co., Inc. - Novartis AG - Omron Healthcare, Inc. - PARI Respiratory Equipment, Inc. - Philips Healthcare - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/cm...onary_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
What Does This Rejection Mean for Eli Lilly?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 06, 1:00PM CST
In the extremely competitive world of Big Pharma, companies have to be careful to keep all of their ducks in neat little rows. I have made no secret of the fact that I believe Lilly struggles in that regard, and yesterday's surprising announcement...
Regulatory Setback for Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 11:00AM CST
Eli Lilly and partner Boehringer Ingelheim's empagliflozin received Complete Response Letter (CRL)
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin
Brian Orelli, The Motley Fool - Motley Fool - Wed Mar 05, 11:58AM CST
Eli Lilly and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership. As rejections go, this one is pretty minor. ...
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded...
Is This Drug Enough To Revive Hope in Eli Lilly's Pipeline?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 04, 1:30PM CST
Eli Lilly & Co snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk . ...
Morning Movers in Biotech: AstraZeneca PLC, Durata Therapeutics, Inc. and Intercept Pharmaceuticals,
George Budwell, The Motley Fool - Motley Fool - 2 hrs 30 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Fri Mar 14, 7:02AM CDT
AstraZeneca (NYSE:AZN) was downgraded from Neutral to Underweight at JP Morgan today. The stock closed yesterday at $65.27 on volume of 2.8 million shares, above average daily volume of 2.4 million. AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
AstraZeneca to Sell Cheshire Research Site - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:30AM CDT
AstraZeneca agreed to sell its Alderley Park center to Manchester Science Parks.
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - Thu Mar 13, 7:31AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
How Will This Latest Setback Affect Eli Lilly?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 11, 8:30AM CDT
Still struggling to revive its drought of approvals, especially after staunchly refusing to succumb to the rest of Big Pharma's strategy of mergers and acquisitions, Eli Lilly suffered another setback for its diabetes pipeline this week when the...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Key Pharmaceutical Executive Joins Mesoblast
GlobeNewswire - Mon Mar 10, 6:49PM CDT
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former Chief Financial Officer of Novartis AG, has joined the Company to support the implementation of corporate finance and strategic objectives.
Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
M2 - Mon Mar 10, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k2mrld/investigation) has announced the addition of the "Investigation Report on China Budesonide Market, 2009-2018" report to their offering. Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year. Budesonide inhalation suspension (trade name ""Pulmicort Respules"") developed by Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It obtained import approval in China in November 2001. Statistics shows that there are more than 30 million asthma patients and over 0.3 billion people suffering from allergic rhinitis in China. According to CRI's investigation on certain sample hospital market in China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011, market growth has slowed down, but it still maintains an annual growth rate of 18%. In April 2013, the patent protection of asthma drug ""Pulmicort Respules"" produced by Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that this has paved the way for generic drug to occupy the market. Budesonide products in Chinese market are still mainly imported drugs from Astra Zeneca, but there are already some Chinese enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group) Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and finished drugs. Through this report, the readers can acquire the following information: - Incidence of Respiratory Disease in China - Market Share of Major Budesonide Manufacturers in Sample Hospitals in China - Sales price of Budesonide in Hospital Market in China - Production Status of Budesonide Generic Drug in China - Major Budesonide Manufacturers in China - Share of Budesonide in Different Dosage Forms in China Hospital Market - Prospect of China Budesonide Market The author recommends the report to the following: - Budesonide Manufacturers - Medical Institutions - Investors /Research Agencies Focusing on Respiratory Drug Market Key Topics Covered: 1 Relevant Concepts of Budesonide 2 Market Overview of Budesonide in China 3 Investigation on Sales Value of Budesonide in China, 2009-2013 4 Investigation on Market Share of Major Budesonide Manufacturers in China, 2009-2013 5 Investigation on Market Size of Budesonide by Dosage Form in China, 2009-2013 6 Reference Price of Budesonide Produced by Different Enterprises in China Hospital Market, 2013 7 Analysis on Major Budesonide Manufacturers in China, 2009-2013 8 Prospect of China Budesonide Market, 2014-2018 Companies Mentioned - AstraZeneca Australia - AstraZeneca plc. - Lunan Better Pharmaceutical Co., Ltd. - Synmosa Biopharma Corp. For more information visit http://www.researchandmarkets.com/research/k2...estigation
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Pulmonary Drug Delivery Systems Market Forecast, 2013 - 2019 Report
M2 - Fri Mar 07, 3:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/cm5685/pulmonary_drug) has announced the addition of the "Pulmonary Drug Delivery Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' This report studies the current scenario as well as the future market potential for pulmonary drug delivery systems, globally. The market for pulmonary drug delivery systems has been segmented into three major product types, namely, metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. The market for these systems has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence and technological developments. On the basis of therapeutic application, the market has been segmented into asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. Geographically, the market for pulmonary drug delivery systems has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. The report also provides a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global pulmonary drug delivery systems market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the global pulmonary drug delivery systems market such as AstraZeneca plc, CareFusion Corporation, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., 3M Health Care, Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Philips Respironics, Inc., Allied Healthcare Products, Inc., and GF Health Products Inc. Key Topics Covered: Preface Executive Summary Market Overview Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2011 - 2019 (USD Million) Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2011 - 2019 (USD Million) Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - 3M Health Care - Allied Healthcare Products, Inc. - AstraZeneca plc - Boehringer Ingelheim - CareFusion Corporation - GF Health Products, Inc. - GlaxoSmithKline plc - Merck & Co., Inc. - Novartis AG - Omron Healthcare, Inc. - PARI Respiratory Equipment, Inc. - Philips Healthcare - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/cm...onary_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
What Does This Rejection Mean for Eli Lilly?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 06, 1:00PM CST
In the extremely competitive world of Big Pharma, companies have to be careful to keep all of their ducks in neat little rows. I have made no secret of the fact that I believe Lilly struggles in that regard, and yesterday's surprising announcement...
Regulatory Setback for Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 11:00AM CST
Eli Lilly and partner Boehringer Ingelheim's empagliflozin received Complete Response Letter (CRL)
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin
Brian Orelli, The Motley Fool - Motley Fool - Wed Mar 05, 11:58AM CST
Eli Lilly and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership. As rejections go, this one is pretty minor. ...
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded...
Is This Drug Enough To Revive Hope in Eli Lilly's Pipeline?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 04, 1:30PM CST
Eli Lilly & Co snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk . ...
(0)
(0)AstraZeneca PLC (AZN) Stock Research Links
Scroll down for more posts ▼